United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline hydrochloride, usp is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery per

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dr chet's pty ltd - piperonyl butoxide | melaleuca alternifolia oil | permethrin (25:75::cis:trans) - parasiticides - dog | bitch | castrate | puppy - flea | louse | skin conditions | bacterial skin conditions | ctenocephalides spp. | dermatoses | eczema | fungal skin conditions | ground fleas | nonspecific skin conditions | skin treatment

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dr chet's pty ltd - piperonyl butoxide | pyrethrins - parasiticides - cat | dog | dog - puppy | kitten | bitch | castrate | cat - queen | cat - tom | kitten | puppy | young cat - coat conditioner | flea - ctenocephalides spp. | louse

United Kingdom - English - myHealthbox

dr. reddy’s laboratories (uk) ltd - docetaxel - concentrate for solution for infusion (sterile concentrate) - 20mg/ml - taxanes - in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with: • operable node-positive breast cancer • operable node-negative breast cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - candesartan cilexetil,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - candesartan cilexetil,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - candesartan cilexetil,hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 20 mg - tablet, enteric coated - excipient ingredients: purified talc; carnauba wax; purified water; light magnesium oxide; iron oxide yellow; hyprolose; ethylcellulose; ethanol absolute; titanium dioxide; hypromellose phthalate; mannitol; diacetylated monoglycerides; magnesium stearate - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rabeprazole sodium, quantity: 10 mg - tablet, enteric coated - excipient ingredients: mannitol; purified water; carnauba wax; hypromellose phthalate; diacetylated monoglycerides; hyprolose; ethanol absolute; titanium dioxide; purified talc; magnesium stearate; ethylcellulose; iron oxide red; light magnesium oxide - ? treatment and prevention of relapse of gastro-oesophageal reflux disease,? symptomatic treatment of gastro-oesophageal reflux disease,? treatment of duodenal ulcers,? treatment of gastric ulcers.,patients whose gastric and duodenal ulceration is not associated with ingestion of non-steroidal antiinflammatory,drugs (nsaids) usually require treatment with antimicrobial agents in addition to,antisecretory drugs whether on first presentation or on recurrence.,it is also indicated, in combination with clarithromycin and amoxycillin, for,? eradication of helicobacter pylori in patients with peptic ulcer disease or chronic gastritis,? healing of peptic ulcers in patients with helicobacter pylori associated ulcers.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - simvastatin, quantity: 40.005 mg - tablet - excipient ingredients: butylated hydroxyanisole; magnesium stearate; lactose monohydrate; ascorbic acid; microcrystalline cellulose; pregelatinised maize starch; citric acid; titanium dioxide; hypromellose; hyprolose; iron oxide yellow; iron oxide red; iron oxide black - simvastatin-drla is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with simvastatin-drla, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. simvastatin-drla is indicated in patients at high risk of chd (with or without hypercholesterolaemia), including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. simvastatin-drla is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-mena